. UK and US health databases should be`mined' for existing information on access problems for under-served and socially excluded populations . Dif®culties exist in de®ning care at the end of life, compounded in the USA by the system of reimbursement. We should therefore consider a measurement of provider in¯uences on access . This area should include a review of existing models of care and the evidence of success or failure among speci®c under-served populations in geographic areas (rural, inner city). How does access to care differ by setting?
How does the quality of care differ by setting? An intriguing issue is the extent to which palliative care lengthens life and increases the need for health resources . Changes in the HIV disease trajectory must be evaluated in relation to palliative care decision-making. This should also include reasons why people choose to stop curative or life maintaining therapy, such as HIV pharmaceuticals or renal dialysis, and the role of advance directives . We need to evaluate the attitudes of palliative care towards under-served groups, and strategies to improve attitudes and access. Systematic reviews are needed to identify qualitative and quantitative measurement issues that require development. The limited number of successful randomized controlled trials may re¯ect the particular methodological dif®culties palliative care poses for trial design. Problems of recruitment, attrition and the vulnerability of patient groups make randomized controlled trials dif®cult. Retrospective studies have a place, but there is a need for more prospective studies with comparison groups. Alternative methods such as economic modelling should be considered.
As regards measurement there is a strong case for evaluation of existing indices rather than development of tools speci®c for palliative care and HIV/AIDS. The best method may be to use core items of a tool with add-on questions depending on the setting or target audience. But caution is needed because inclusion of`closure issues' (sensitive questions) within cognitive questionnaires can be upsetting. Another consideration is whose view one takes when assessing outcomesÐthe patient, the carer or the healthcare professional?
The group stressed the integration of research ®ndings with clinical care for under-served and socially excluded populations. Scienti®c ®ndings should improve access to palliative care, the clinical quality of such care, and its integration with curative care and community support services.
We then identi®ed joint US/UK projects for the short term (1 year) and the longer term (5 years). For the next twelve months the following were proposed:
. Mine the data (e.g. mortality ®les, hospital discharge data) in relation to patterns of serviceÐpalliative care/ outcomes/under-served/socially excluded . Conduct systematic reviews of evidence-based advanced planning for healthcare interventions . Conduct ethnographic studies (e.g. focus groups) on how differing communities access end-of-life care and de®ne barriers to care . Revalidate existing tools for this population (palliative care) . Organize UK±US exchanges of postdoctoral students, fellowships, paired postdoctoral experiences.
In the next 5 years:
. Conduct a prospective cohort study to de®ne illness (especially for HIV/AIDS patients), construct functional trajectory models to de®ne criteria for decision-making, and identify the main determinants of palliative treatment decisions . Compare receipt of palliative care versus non-palliative care in relation to survival and quality of life, to understand the interplay of race, social class and the communityÐhow the community impacts on treatment decisions . Organize community intervention demonstrations to reduce identi®ed access barriers; examine differences between the US and the UK in treatment decisions . Mount a prospective cohort study from diagnosis of advanced disease to death, studying the cost/quality of life and quality of care/advanced care planning . Evaluate approaches to delivering palliative care for recent immigrants.
